[贝伐单抗在胸部肿瘤学中的应用：结果与实际情况]

[Bevacizumab in thoracic oncology: results and practical aspects].

作者信息

Dansin É, Cousin S, Lauridant G, Mennecier B

机构信息

Département de cancérologie générale, CLCC Oscar-Lambret, 3, rue Fréderic-Combemale, BP 307, 59020 Lille cedex, France.

出版信息

Rev Pneumol Clin. 2013 Jun;69(3):159-69. doi: 10.1016/j.pneumo.2013.02.006. Epub 2013 Apr 15.

DOI:10.1016/j.pneumo.2013.02.006

PMID:23597632

Abstract

Bevacizumab (Avastin(®)) is the first antiangiogenic therapy approved in non-small cell lung cancer (NSCLC). It is also currently the only agent in this family approved in NSCLC. This review focuses on results of clinical trials assessing bevacizumab in thoracic oncology. It also provides to clinicians practical advices for its prescription.

摘要

贝伐单抗（阿瓦斯汀（®））是首个被批准用于非小细胞肺癌（NSCLC）的抗血管生成疗法。它也是目前该类药物中唯一被批准用于非小细胞肺癌的药物。本综述重点关注评估贝伐单抗在胸部肿瘤学中应用的临床试验结果。它还为临床医生提供了关于其处方的实用建议。